Ga-68 DOTATOC Market: Overview
[68Ga]Ga-DOTA-TOC or Ga-68 DOTATOC is a radiopharmaceutical that has gained regulatory approval for imaging of somatostatin receptor (SSTR) positive gastroenteropancreatic neuroendocrine tumors (NET) when positron emission tomography (PET) is used. It is a combination of radionuclide 68Ga and the somatostatin analogue DOTA-TOC. Industry investments in the Ga-68 DOTATOC market have risen on the back of the use of Ga-68 DOTATOC in the localization of SSTR-positive NETs. The molecule has been utilized in PET for staging and restaging of NET and is useful in the management of NET. They are suitable for both adult and pediatric patients. It is administered as an intravenous injection.
The growing adoption of PET in identifying and evaluating the extent of NET is a direct driver for the growth in the Ga-68 DOTATOC market. Further, they are helpful in the evaluation of treatment response. The demand for PET tracers has gained traction in nuclear medicine, and helps in managing prevalence of neuroendocrine tumors. They prominently assist biomarker findings.
Do you want to assess potential implications of COVID-19 on your business and emerge with agility ? Grab an exclusive PDF Brochure for this report!
Ga-68 DOTATOC Market: Key Trends
The global Ga-68 DOTATOC market is evolving on the back of increasing incidence of NET, since the improvement in diagnosis rate is a result of imaging modalities. In the U.S. alone, more than 12,000 people are diagnosed with NET. A number of clinical trials including comparison studies have evaluated the sensitivity and specificity of radiopharmaceutical. Increased awareness of NETs along with the strides in nuclear medicine are expanding the outlook of the Ga-68 DOTATOC market.
The rise in adoption of a remarkable imaging agent is a key aspect propelling the product approval of Ga-68 DOTATOC in various countries. Worldwide, over the past few years, theranostic approach has gathered steam in health care, particularly personalized (precision) nuclear medicine, fueling the uptake of Ga-68 DOTATOC in the PET scan. The emergence of new PET tracers is a key trend in the diagnosis of NETs.
The market has also received a significant and steady momentum from pharmacology and pharmacokinetics of somatostatin analogs.
Are you a start-up willing to tailored insights that will help you align operational and strategic goals in growth journey? Grab an exclusive Sample for this report!
Ga-68 DOTATOC Market: Competitive Analysis and Key Developments
In 2019, Ga-68 DOTATOC has been approved by the Food and Drug Administration (FDA) for NET in the U.S. The molecule has already been approved for Austria, Germany, and France. These all paint a promising picture of the future prospects in the Ga-68 DOTATOC market. Stakeholders including industry players are reaping revenue gains from the need for advancing therapy planning in NETs. The market players are keen on expanding the evaluation of treatment response. Small facilities are engaged more in the decentralized preparation of Ga-68 DOTATOC. Key players have also benefited from metaanalysis of the indications that 68Ga-DOTATOC can be used.
However, genuine impediments to the avenue are high costs of diagnostic equipment and lack of physician who can handle radiopharmaceutical. Pancreatic neuroendocrine tumors are a promising segment in the Ga-68 DOTATOC market.
Numerous players are adopting strategic collaboration, acquisitions and mergers to consolidate their shares in the market. Some of the key industry stakeholders in the Ga-68 DOTATOC market are Seimens AG, Synergy Pharmaceuticals, Amgen Inc. Biosynthema, Mayroy SA, Bristol Myers Squibb Company, Eli Lilly & Company, Roche Holding AG, and Pfizer Inc.
Ga-68 DOTATOC Market: Regional Assessment
The global Ga-68 DOTATOC market is expected to see massive revenue potential in North America and Europe. The marked incidence of NETs in the regional populations has propelled the demand. Furthermore, advancements in Diagnostic technologies used in NET and extensive clinical studies on the nuclear medicine are opening new paths of development in the regional market.
Increasing awareness about the NETs in Asia is one of the key growth drivers for new avenues in the Ga-68 DOTATOC market.
This study by TMR is all-encompassing framework of the dynamics of the market. It mainly comprises critical assessment of consumers' or customers' journeys, current and emerging avenues, and strategic framework to enable CXOs take effective decisions.
Our key underpinning is the 4-Quadrant Framework EIRS that offers detailed visualization of four elements:
- Customer Experience Maps
- Insights and Tools based on data-driven research
- Actionable Results to meet all the business priorities
- Strategic Frameworks to boost the growth journey
The study strives to evaluate the current and future growth prospects, untapped avenues, factors shaping their revenue potential, and demand and consumption patterns in the global market by breaking it into region-wise assessment.
The following regional segments are covered comprehensively:
- North America
- Asia Pacific
- Latin America
- The Middle East and Africa
The EIRS quadrant framework in the report sums up our wide spectrum of data-driven research and advisory for CXOs to help them make better decisions for their businesses and stay as leaders.
Below is a snapshot of these quadrants.
1. Customer Experience Map
The study offers an in-depth assessment of various customers’ journeys pertinent to the market and its segments. It offers various customer impressions about the products and service use. The analysis takes a closer look at their pain points and fears across various customer touchpoints. The consultation and business intelligence solutions will help interested stakeholders, including CXOs, define customer experience maps tailored to their needs. This will help them aim at boosting customer engagement with their brands.
2. Insights and Tools
The various insights in the study are based on elaborate cycles of primary and secondary research the analysts engage with during the course of research. The analysts and expert advisors at TMR adopt industry-wide, quantitative customer insights tools and market projection methodologies to arrive at results, which makes them reliable. The study not just offers estimations and projections, but also an uncluttered evaluation of these figures on the market dynamics. These insights merge data-driven research framework with qualitative consultations for business owners, CXOs, policy makers, and investors. The insights will also help their customers overcome their fears.
3. Actionable Results
The findings presented in this study by TMR are an indispensable guide for meeting all business priorities, including mission-critical ones. The results when implemented have shown tangible benefits to business stakeholders and industry entities to boost their performance. The results are tailored to fit the individual strategic framework. The study also illustrates some of the recent case studies on solving various problems by companies they faced in their consolidation journey.
4. Strategic Frameworks
The study equips businesses and anyone interested in the market to frame broad strategic frameworks. This has become more important than ever, given the current uncertainty due to COVID-19. The study deliberates on consultations to overcome various such past disruptions and foresees new ones to boost the preparedness. The frameworks help businesses plan their strategic alignments for recovery from such disruptive trends. Further, analysts at TMR helps you break down the complex scenario and bring resiliency in uncertain times.
The report sheds light on various aspects and answers pertinent questions on the market. Some of the important ones are:
1. What can be the best investment choices for venturing into new product and service lines?
2. What value propositions should businesses aim at while making new research and development funding?
3. Which regulations will be most helpful for stakeholders to boost their supply chain network?
4. Which regions might see the demand maturing in certain segments in near future?
5. What are the some of the best cost optimization strategies with vendors that some well-entrenched players have gained success with?
6. Which are the key perspectives that the C-suite are leveraging to move businesses to new growth trajectory?
7. Which government regulations might challenge the status of key regional markets?
8. How will the emerging political and economic scenario affect opportunities in key growth areas?
9. What are some of the value-grab opportunities in various segments?
10. What will be the barrier to entry for new players in the market?
Note: Although care has been taken to maintain the highest levels of accuracy in TMR’s reports, recent market/vendor-specific changes may take time to reflect in the analysis.